



PHARMACY AND POISONS BOARD
HONG KONG
香港藥劑業及毒藥管理局

Your Ref. :
貴處檔號

Our Ref. : DH DO PRIE/1-55/1
本局檔號

Tel. No. : 3974 4175
電 話

Fax No. : 2803 4962
圖文傳真

Drug Office
Department of Health
Suites 2002-05, 20/F, AIA Kowloon Tower,
Landmark East, 100 How Ming Street,
Kwun Tong, Kowloon, Hong Kong
香港九龍觀塘巧明街100號
Landmark East 友邦九龍大樓
20樓2002-05室
衛生署藥物辦公室

16 October 2026

To: Applicants/certificate holders for registration of pharmaceutical products
containing pomalidomide

Dear Sir/Madam,

Risk Minimisation Measures for Pomalidomide

The Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances) Committee (the Committee) under the Pharmacy and Poisons Board decided in the meeting on 15 October 2026 that the certificate holders of registered pharmaceutical products containing pomalidomide are required to implement risk minimisation measures. The measures shall include:

- (i) *Controlled access program: Registration program for doctors, pharmacists/pharmacies and patients shall be available. Limitation on drug supply duration shall be set;*
- (ii) *Training and educational materials for healthcare professionals;*
- (iii) *Educational materials and agreement form for patients; and*
- (iv) *Certificate holders' authorization for each dispensing (e.g. Prescription Authorization Form).*

Any modifications to the above measures shall be made with justification and that may be submitted to the Committee for consideration.

For further enquiries on the registration matters of pharmaceutical products, please contact the Drug Office at 3974 4175.

Yours faithfully,



(Y. F. YEUNG)
Secretary,
Pharmacy and Poisons (Registration of
Pharmaceutical Products and Substances)
Committee

c.c. 7-15/3, Product Files